Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins
Open Access
- 1 July 1977
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 146 (1) , 22-33
- https://doi.org/10.1084/jem.146.1.22
Abstract
Cleavage of C3 [3rd component of complement] by the alternative complement pathway occurs in at least 2 distinct phases: continuous low grade generation of C3b [subunit b of C3] by the interaction of native C3, B, .hivin.D and P [properdin]; and subsequent amplified cleavage of C3 by the interaction of C3b, B, .hivin.D and P which forms the amplification convertase, P,C3b,Bb. Transition to C3b-dependent amplification is necessary to achieve substantial C3 cleavage and is normally limited by the combined action of C3b inactivator (C3bINA) and .beta.1H. An activator of the alternative pathway, such as rabbit erythrocytes (Er), provides sites that protect bound C3b and P,C3b,Bb from the action of these regulatory proteins and permits C3b deposited by the low grade fluid phase reaction to assemble a membrane-associated amplification convertase which can deposit additional protected C3b. Under conditions in which the control proteins, C3bINA and .beta.1H, almost completely inactivated C3b bound to sheep erythrocytes (Es) which do not activate the alternative pathway) the function of C3b bound to Er was diminished by less than 1/5. The P-stabilized amplification convertase on Er was 10-fold less sensitive to .beta.1H-mediated decay-dissociation than the convertase on Es. The addition of Er to a regulated mixture of purified C3, B, .hivin.D, P, C3bINA and .beta.1H resulted in amplified inactivation of C3 and B by formation of the amplification convertase on Er as indicated by its lysis with subsequent exposure to C3-C9. Es did not advance the low grade fluid phase inactivation of C3 and B to amplified inactivation and the cell was not converted to an intermediate susceptible to lysis by C3-C9. Since Er and Es did not differ in their inefficient fixation of C3b generated during an unregulated fluid phase reaction, the activating capacity of Er must reside in its protection of bound C3b and P,C3b,Bb from the regulatory proteins rather than in enhanced capacity to bind C3b from the fluid phase. When the reaction is limited to low grade fluid phase turnover, introduction of Er but not Es results in a 100-fold increase in the deposition of C3b, indicating that surface-dependent activation of the alternative pathway is characterized by efficient deposition of C3b on the initiating surface. The activating surfaces advance the interaction of the alternative pathway proteins to the amplification phase because of the selective inability of the regulatory proteins to deal with their substrates when deposited on these surfaces and results in a specificity that is not necessarily dependent on adaptive immunity.Keywords
This publication has 39 references indexed in Scilit:
- Activation of the alternative complement pathway due to resistance of zymosan-bound.Proceedings of the National Academy of Sciences, 1977
- Modulation of the alternative complement pathways by beta 1 H globulin.The Journal of Experimental Medicine, 1976
- Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.The Journal of Experimental Medicine, 1976
- Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.The Journal of Experimental Medicine, 1976
- Control of the amplification convertase of complement by the plasma protein beta1H.Proceedings of the National Academy of Sciences, 1976
- Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.The Journal of Experimental Medicine, 1975
- C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.1971
- ISOLATION OF ß1F-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENTThe Journal of Experimental Medicine, 1965
- AN ALTERNATIVE MECHANISM FOR THE PROPERDIN SYSTEMThe Journal of Experimental Medicine, 1958
- The Properdin System and Immunity: I. Demonstration and Isolation of a New Serum Protein, Properdin, and Its Role in Immune PhenomenaScience, 1954